March 11 (Reuters) - Regenxbio said on Wednesday that interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued ...
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...
New Indian clinical guidelines warn that age-related muscle loss, or sarcopenia, is an under-recognised health risk affecting ...
As a physician who prescribes GLP-1 medications like Ozempic, Wegovy, semaglutide, and tirzepatide, I explain why increasing ...
Podiatrists break down the latest findings.
Parkinson’s disease doesn’t only mean a tremor and falls. It can cause insomnia, memory issues and impulsive behaviour. And it affects men and women differently.
At the 2026 MDA Conference in Orlando, Genethon unveiled new two‑year efficacy data for its gene therapy candidate GNT0004, a key milestone for Duchenne muscular dystrophy research.
Add Yahoo as a preferred source to see more of our stories on Google. A single self‑amplifying RNA injection that boosts a heart‑healing peptide cut scarring and improved function after heart attacks ...
Biomaterials are taking medicine by storm – explore some recent preclinical advances in the field that may yield therapeutic benefits.
Amid the pull and pressure of Mother’s Day, Strong Like Mum founder Shakira Akabusi writes about what really matters to mums ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results